Innovax-ILT (--) concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain HVT/ILT-138 (cell-associated), expressing gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Product identification

Medicine name:
Innovax-ILT (--) concentrate and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain HVT/ILT-138 (cell-associated), expressing gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Target species:
Chicken

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain HVT/ILT-138 (cell-associated), expressing gD and gI glycoproteins genes of Infectious laryngotracheitis virus, Live

Presentation_strength:$10^{3.1}$ – $10^{4.1}$ PFU Reference:In house Comments:per dose Index:0

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Chicken**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Bulgaria , Cyprus , Czechia , France , Germany , Greece , Hungary , Netherlands , Poland , Spain , United Kingdom (Northern Ireland)

Package description:

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 4000 doses

Packaging:Concentrate: ampoule (glass), Package_size:Concentrate: 1 ampoule, Content:Concentrate: 2000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
3/07/2015

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
3/07/2015

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 26/05/2023

Download

ema-puar-innovax-ilt-v-3869-par-en.pdf